Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MTCP1
REST API REST API
Homo sapiens
MTCP1 is differentially expressed in 255 experiments: 99 organism parts: bone marrow, heart, ... (97 more);, 142 disease states: normal, control, ... (140 more);, 72 cell types 171 cell lines 38 compound treatments and 69 other conditions.
Synonyms P13MTCP1, p8MTCP1
Orthologs Mtcp1 (Mus musculus)   ENSGALG00000023937 (Gallus gallus)   LOC679930 (Rattus norvegicus)   MTCP1 (Canis familiaris)   MTCP1 (Bos taurus)   (Compare orthologs)
Gene Ontology Term cell proliferation, mitochondrion
InterPro Term TCL1_MTCP1
UniProt Accession P56278
Search EB-eye ENSG00000214827
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (33 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-5823, E-GEOD-3529
K562
2
E-GEOD-96, E-GEOD-24147
BT474
2
E-MEXP-440, E-MTAB-62
MCF-10A
2
E-GEOD-14990, E-TABM-420
MDA468
2
E-MEXP-440, E-MTAB-62
HCC95
1
E-MTAB-62
165 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-22529, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (33 experiments)

Factor Value U/D Experiments
cardiac myocyte
2
E-AFMX-5, E-MTAB-25
1
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
purified B cells from peripheral blood from donors 60 years of age and older
1
E-GEOD-22529
trabecular meshwork cell
1
E-GEOD-492
66 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-22529, E-GEOD-15960, E-GEOD-2466, ... (43 experiments)

Factor Value U/D Experiments
ischemic cardiomyopathy
2
E-GEOD-1145, E-MTAB-62
prostate cancer
2
E-GEOD-6919, E-MTAB-62
acute promyelocytic leukemia
2
E-GEOD-96, E-MTAB-62
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
glioblastoma
2
E-GEOD-4290, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-GEOD-96
136 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, ... (25 experiments)

Factor Value U/D Experiments
none
2
4
E-MEXP-1958, E-GEOD-412, E-GEOD-5824, E-GEOD-20719, E-GEOD-7400, ... (6 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
unknown
1
E-GEOD-7307
granulocyte-colony stimulating factor
1
E-GEOD-7400
anti-CD3 + anti-CD28
1
E-GEOD-7307
4-hydroxytamoxifen
1
1
E-MEXP-2241
32 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-2171, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-6710, E-GEOD-22513, E-MEXP-1251, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-GEOD-4667, E-MEXP-2283, E-MEXP-958, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-21887

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-GEOD-7578, E-GEOD-17385, E-GEOD-6431, ... (6 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-22056, E-GEOD-1045, E-GEOD-3494, E-GEOD-2466, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-22278, E-GEOD-10315, ... (13 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, E-GEOD-360 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-1676, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2508, E-GEOD-2466

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.368 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM